| Orlistat reverse fatty infiltration and improves hepatic fibrosis in obese patients with nonalcoholic steatohepatitis (NASH). | |
| | |
MedLine Citation:
|
PMID: 17404856 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Nonalcoholic steatohepatitis (NASH) may cause progressive hepatic fibrosis, cirrhosis, and hepatocellular carcinoma. Treatment, thus far, has been restricted to diet and weight loss, but without compelling results. In this study we aimed to evaluate the efficacy of orlistat therapy in obese patients with NASH. Fourteen obese patients with NASH underwent liver biopsy prior to and subsequent to 6 months treatment with orlistat (120 mg tid). Hepatic fat extension was graded as normal, mild, moderate, or severe. Hepatic fibrosis was scored on a scale from 0 to 4, with 0 denoting no fibrosis and 4, cirrhosis. Portal inflammation was scored as 0-3, with 0 = normal, 1 = mild, 2 = moderate, and 3 = severe inflammation. Fourteen patients had NASH associated with diabetes, hyperlipidemia, or obesity. Orlistat reduced fatty infiltration in 10 patients (70%; P<0.01), 3 of whom had normal liver fat content after treatment. Orlistat improved inflammatory activity by 2 grades in 28% and by 1 grade in 50% of patients and effected no change in 22% of patients. Five patients (35%) returned to normal inflammatory activity. Orlistat improved hepatic fibrosis by 2 grades in three patients (21%) and by 1 grade in seven patients (50%). There was no change in four patients (28%). Orlistat lowered aminotransferases levels, total cholesterol, triglycerides and low-density lipoprotein, respectively. Insulin resistance index and malonyl dialdehyde levels improved significantly after orlistat therapy, whereas HbAic remained unchanged. In conclusion, in obese patients with NASH, liver fibrosis and inflammation improved after therapy with orlistat. |
| | |
Authors:
|
Osamah Hussein; Masha Grosovski; Sorina Schlesinger; Sergio Szvalb; Nimer Assy |
Related Documents
:
|
11454316 - Amelioration of steroid-resistant chronic graft-versus-host-mediated liver disease via ... 579516 - Heparin elimination in patients with liver cirrhosis. 19558966 - Hepatic anaplerotic outflow fluxes are redirected from gluconeogenesis to lactate synth... 8014446 - Autoimmune liver disease in patients with primary sjögren's syndrome. 9494846 - Low dose interferon gamma for refractory crohn's disease. 16120036 - Assessment of dose selection attributes with audible notification in insulin pen devices. |
Publication Detail:
|
Type: Journal Article Date: 2007-04-03 |
Journal Detail:
|
Title: Digestive diseases and sciences Volume: 52 ISSN: 0163-2116 ISO Abbreviation: Dig. Dis. Sci. Publication Date: 2007 Oct |
Date Detail:
|
Created Date: 2007-09-06 Completed Date: 2007-10-25 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7902782 Medline TA: Dig Dis Sci Country: United States |
Other Details:
|
Languages: eng Pagination: 2512-9 Citation Subset: AIM; IM |
Affiliation:
|
Department of Internal Medicine A, Sieff Government Hospital, Safed, Israel. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Biopsy Body Mass Index Enzyme Inhibitors / therapeutic use* Fatty Liver / complications, drug therapy*, pathology Female Follow-Up Studies Humans Lactones / therapeutic use* Lipase / antagonists & inhibitors Liver Cirrhosis / complications, drug therapy*, pathology Male Middle Aged Obesity / blood, complications* Recovery of Function / drug effects* Severity of Illness Index Transaminases / blood Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Enzyme Inhibitors; 0/Lactones; 96829-58-2/orlistat; EC 2.6.1.-/Transaminases; EC 3.1.1.3/Lipase |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Outcomes of cystic lesions in the pancreas after extended follow-up.
Next Document: Dietary glutamine supplementation prevents mucosal injury and modulates intestinal epithelial restit...